Insulet Co. (NASDAQ:PODD) Receives $239.18 Consensus Price Target from Brokerages

Shares of Insulet Co. (NASDAQ:PODD) have earned a consensus rating of “Moderate Buy” from the eighteen analysts that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $239.18.

PODD has been the topic of several research analyst reports. Redburn Atlantic initiated coverage on Insulet in a research note on Thursday, May 30th. They issued a “buy” rating and a $235.00 price objective on the stock. OTR Global reissued a “mixed” rating on shares of Insulet in a research report on Monday, June 10th. Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target on the stock in a research report on Tuesday, May 7th. Raymond James reduced their price target on Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Finally, Barclays dropped their price objective on Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a report on Monday, May 13th.

Insulet Trading Down 2.5 %

Insulet stock opened at $201.80 on Thursday. The stock has a market cap of $14.13 billion, a PE ratio of 61.15, a P/E/G ratio of 3.73 and a beta of 1.14. The stock has a 50-day moving average price of $183.59 and a 200 day moving average price of $186.47. Insulet has a 52 week low of $125.82 and a 52 week high of $295.00. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The firm had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. During the same period last year, the company earned $0.23 EPS. The firm’s quarterly revenue was up 23.3% on a year-over-year basis. Equities research analysts predict that Insulet will post 3.11 earnings per share for the current fiscal year.

Insider Activity at Insulet

In related news, SVP Mark N. Field sold 2,131 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the transaction, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Insulet news, SVP Mark N. Field sold 1,500 shares of the business’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the transaction, the senior vice president now owns 12,875 shares in the company, valued at approximately $2,574,485. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mark N. Field sold 2,131 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.43, for a total value of $405,806.33. Following the transaction, the senior vice president now owns 14,375 shares of the company’s stock, valued at approximately $2,737,431.25. The disclosure for this sale can be found here. Insiders sold 13,931 shares of company stock worth $2,636,286 in the last 90 days. 0.47% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

Several institutional investors have recently modified their holdings of the company. Capital Research Global Investors lifted its holdings in shares of Insulet by 19.7% in the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after buying an additional 1,556,455 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock valued at $1,405,328,000 after buying an additional 169,506 shares during the period. Baillie Gifford & Co. lifted its holdings in shares of Insulet by 18.9% in the first quarter. Baillie Gifford & Co. now owns 1,442,279 shares of the medical instruments supplier’s stock valued at $247,207,000 after buying an additional 229,520 shares during the period. Norges Bank acquired a new stake in shares of Insulet in the fourth quarter valued at $227,655,000. Finally, William Blair Investment Management LLC lifted its holdings in shares of Insulet by 3.7% in the first quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock valued at $163,219,000 after buying an additional 33,579 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.